Advanced Search

2022 Vol. 4, No. 23

Preplanned Studies
SARS-CoV-2 Aerosol Transmission Through Vertical Sanitary Drains in High-Rise Buildings — Shenzhen, Guangdong Province, China, March 2022
Keyang Lyu, Siyang Feng, Xia Li, Qin Wang, Xiaoning Zhao, Shuyuan Yu, Ping Zheng, Jiajia Ji, Guomin Chen, Jing Liang, Tao Lan, Jinshu Feng, Shuai Jiang, Jianhua Lu, Tianlong Xia, Chaoqiong Peng, Tiejian Feng, Dongqun Xu
2022, 4(23): 489-493. doi: 10.46234/ccdcw2022.108
Abstract(14595) HTML (468) PDF 8964KB(66)
Abstract:
What is already known about this topic?

Aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via sanitary pipelines in high-rise buildings is possible, however, there is a lack of experimental evidence.

What is added by this report?

The field simulation experiment confirmed the existence of a vertical aerosol transmission pathway from toilet flush-soil stack-floor drains without water seal. This report provided experimental evidence for vertical aerosol transmission of clustered outbreaks on 18 floors of a 33-story residential building.

What are the implications for public health practice?

The water seal on floor drains is a necessary barrier to prevent the risk of vertical aerosol transmission of infectious disease pathogens in buildings. It is necessary not only to have a U-shaped trap in the drainage pipe, but also to be filled with water regularly.

An Analysis of Life-Year Lost Due to COVID-19 — 34 Countries, December 2019–March 2021
Shan Jiang, Dan Cai, Daqin Chen, Yawen Jiang
2022, 4(23): 494-498. doi: 10.46234/ccdcw2022.109
Abstract(5608) HTML (198) PDF 436KB(48)
Abstract:
What is already known about this topic?

The coronavirus disease 2019 (COVID-19) pandemic has caused severe health consequences. Though most COVID-19 deaths occurred among very old people, their life-year loss might be very large because of their life expectancy at that age.

What is added by this report?

This study quantified how many years of life were lost due to COVID-19 in 34 countries. COVID-19 caused 9 to 21 years of life lost (YLL) per deceased patient. East Asia and Oceania had substantially lower per capita YLL than North America and Europe. Among all countries included, the United States had the greatest total YLL, Peru had the largest YLL per 100,000 people, and Mexico had the largest YLL per 100,000 COVID-19 patients.

What are the implications for public health practice?

The YLL quantification indicated that the vulnerable population, especially the elderly, should be protected under careful public health measures to reduce their YLL. It also implied that it might be too early to lift anti-epidemic restrictions now, since the extreme disproportionate consequences (total and per-capita YLL) in different countries underscored the scrutinization over the variation in disease control strategies to optimize future disease control and prevention.

Commentary
Measuring the Effect of COVID-19 Pandemic on Mortality: Review and Prospect — China, 2021
Jinlong Lin, Guogui Huang, Yue Wei, Lijun Pei
2022, 4(23): 499-503. doi: 10.46234/ccdcw2022.110
Abstract(18462) HTML (259) PDF 210KB(63)
Abstract:

Current progress in measuring the effect of the pandemic on mortality is limited. Few studies have comprehensively and systematically elucidated the mechanism through which the pandemic affects mortality and what indicators are valid to capture such an effect. This paper presents a comprehensive analysis regarding the multifaceted effects of coronavirus disease 2019 (COVID-19) on mortality and its measurements [i.e., confirmed deaths per million people (CDPMP), case fatality rate (CFR), infection fatality risk (IFR), excess mortality P-score (EMPS), and life expectancy (LE)]. It was revealed that both data collection efforts and measurements on mortality due to COVID-19 were far from perfect and discussed the importance of accurate, prompt, and accessible data by any government over the course of fighting against the COVID-19 pandemic. It is believed that the biggest challenge in measuring the effect of the COVID-19 pandemic on mortality lies not in the construction of indicators at the academic level, but in the collection of data at the practical level. Thus, it is suggested to take measures to better monitor the development of the pandemic and mitigate the increasing burdens borne by the public health systems by improving the tracking system of mortality, standardizing the diagnosis of COVID-19’s deaths, and disclosing mortality data.

Methods and Applications
Field Evaluation of a Duplex RT-RAA Assay for Rapid Detection of SARS-CoV-2 — Hebei Province, China, January 2021
Ruiqing Zhang, Shunxiang Qi, Jiandong Li, Shiyou Liu, Guangyue Han, Xinxin Shen, Qi Li, Wenbo Xu, Xuejun Ma
2022, 4(23): 504-508. doi: 10.46234/ccdcw2022.111
Abstract(3581) HTML (256) PDF 332KB(28)
Abstract:
Introduction

Recently, a local cluster epidemic has occurred in Shijiazhuang City, Hebei Province. Failure to promptly identify patients with fever in rural areas was the major reason for this epidemic.

Methods

We presented the field evaluation of a new real-time reverse transcription recombinase-aided amplification (RT-RAA) kit incorporating an endogenous internal control in a single-tube format, completed at the Hebei CDC from January 17, 2021 to January 27, 2021.

Results

We evaluated the diagnostic performance of RT-RAA assay using automatic extracted RNA of 808 clinical samples. Compared with reverse transcriptase real-time quantitative PCR (qRT-PCR), RT-RAA kit achieved 92.41% sensitivity, 98.78% specificity and a 96.29% coincidence rate, demonstrating an excellent agreement between the RT-RAA assay and qRT-PCR assay. Furthermore, 58 samples were extracted using a manual extraction method within 5 minutes, but only samples with high nucleic acid concentration (cycle threshold value not higher than 32) could be stably detected.

Discussion

The RT-RAA is more suitable to meet the needs of rapid, sensitive, and accurate detection in community-level medical institutions.

Novaferon Effectively Inhibits Ancestral SARS-CoV-2 and Omicron Variant in Vitro, 2022
Fei Ye, Baoying Huang, Li Zhao, Yao Deng, Jiao Ren, Wenjie Tan
2022, 4(23): 509-512. doi: 10.46234/ccdcw2022.112
Abstract(4266) HTML (269) PDF 305KB(33)
Abstract:
Introduction

To identify Novaferon (Nova), a novel recombinant protein of interferon (IFN)-α, antiviral activity against ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Omicron variant in vitro.

Methods

Vero cells were infected with SARS-CoV-2 and Omicron variant in a biosafety level-3 laboratory. And viral replications were accessed using quantitative real-time reverse transcription polymerase chain reaction (RT-PCR).

Results

Results demonstrated that Nova has effective inhibition against ancestral SARS-CoV-2 and Omicron variant in vitro.

Discussion

The in vivo effects of Nova need to be further tested in animal models. And large-scale randomized double-blind clinical trials are needed to reveal its potentially clinical application.